EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Lihong Wang, Lufang Zhang, Louisa Chard Dunmall, Yang Yang Wang, Zaiwen Fan, Zhenguo Cheng, Yaohe Wang

Cancer Letters · 2024-06 · 591 · 216871

DOI: 10.1016/j.canlet.2024.216871 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-06. Verfasst von Lihong Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Air Force Medical Center, PLA, Beijing, China; National Centre for International Research in Cell and Gene Therapy, Sino Brit…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms, Tumor Microenvironment, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR-T) cell therapy, as an adoptive immunotherapy, is playing an increasingly important role in the treatment of malignant tumors. CAR-T cells are referred to as "living drugs" as they not only target tumor cells directly, but also induce long-term immune memory that has the potential to provide long-lasting protection. CD19.CAR-T cells have achieved complete response rates of over 90 % for acute lymphoblastic leukemia and over 60 % for non-Hodgkin's lymphoma. However, the response rate of CAR-T cells in the treatment of solid tumors remains extremely low and the side effects potentially severe. In this review, we discuss the limitations that the solid tumor microenvironment poses for CAR-T application and the solutions that are being developed to address these limitations, in the hope that in the near future, CAR-T cell therapy for solid tumors can attain the same success rates as are now being seen clinically for hematological malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveNeoplasmsTumor MicroenvironmentReceptors, Chimeric AntigenHumansT-LymphocytesAnimalsReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

CAR-TLogic gateSolid tumorTumor microenvironment

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Oncology, Air Force Medical Center, PLA, Beijing, China; National Centre for International Research in Cell and Gene Therapy, Sino British Research Centre for Molecular Oncology, State Key Laboratory of Es…
  • National Centre for International Research in Cell and Gene Therapy, Sino British Research Centre for Molecular Oncology, State Key Laboratory of Esophageal Cancer Prevention & Treatment, School of Basic Medical Science…
  • Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Department of General Pediatrics, Newham General Hospital, E13 8SL, London, United Kingdom.
  • Department of Oncology, Air Force Medical Center, PLA, Beijing, China.

Förderung

  • UKRI Medical Research Council

Zitieren

APA

Wang, L., Zhang, L., Dunmall, L. C., Wang, Y. Y., Fan, Z., Cheng, Z., & Wang, Y. (2024). The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors. Cancer Letters, 591, 216871. https://doi.org/10.1016/j.canlet.2024.216871

Vancouver

Wang L, Zhang L, Dunmall LC, Wang YY, Fan Z, Cheng Z, et al. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors. Cancer Letters. 2024;591:216871. doi:10.1016/j.canlet.2024.216871

BibTeX
@article{Wang2024,
  author = {Wang, Lihong and Zhang, Lufang and Dunmall, Louisa Chard and Wang, Yang Yang and Fan, Zaiwen and Cheng, Zhenguo and Wang, Yaohe},
  title = {The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors},
  journal = {Cancer Letters},
  year = {2024},
  volume = {591},
  pages = {216871},
  doi = {10.1016/j.canlet.2024.216871}
}
Kostenlos starten →